Concord Biotech Shares Show 50% Fall Today: Why This Jhunjhunwala-Backed Stock Is Not Actually Crashing

Concord Biotech’s share price appeared to plunge nearly 50% on November 4 after a 1:1 bonus share adjustment. Here’s what changed for shareholders, how the revised price works, and what investors should know.

Concord Biotech Ltd, a pharmaceutical company associated with the late investor Rakesh Jhunjhunwala’s family, caught investors’ attention on Wednesday, November 4, 2026, after its shares appeared to decline by nearly 50% on certain trading platforms.

However, the dramatic fall did not represent an equivalent loss in shareholder wealth. The apparent decline was largely the result of the stock trading on an ex-bonus basis following the company’s previously announced 1:1 bonus issue.

Under the corporate action, eligible shareholders are entitled to receive one additional equity share for every existing share held. As a result, the number of shares held by an eligible investor doubles, while the theoretical price per share is adjusted to approximately half its previous level.

Concord Biotech shares had closed at ₹1,229.90 on Tuesday, November 3. Following the bonus adjustment, the stock opened at around ₹610 on Wednesday.

The difference between those two prices may appear alarming when viewed without accounting for the corporate action. However, the appropriate comparison is with the bonus-adjusted reference price rather than the previous day’s unadjusted closing price.

Why Is Concord Biotech Showing a 50% Fall Today?

The primary reason behind the apparent decline is Concord Biotech’s 1:1 bonus share issue.

According to the exchange filing described in the report, the company’s board, at its meeting on October 27, 2026, fixed Wednesday, November 4, as the record date for determining shareholders eligible for bonus equity shares, subject to applicable approvals.

A 1:1 bonus issue means that shareholders receive one new fully paid-up equity share for every existing share they own.

For example, an investor holding 100 Concord Biotech shares before the bonus entitlement would become entitled to another 100 shares, taking the total to 200.

Because the total number of outstanding shares increases, the theoretical market price per share adjusts proportionately.

This is why some brokerage applications may temporarily display an apparent decline of roughly 50% when they compare the ex-bonus trading price with the previous unadjusted closing price.

The adjustment itself does not mean the company has suddenly lost half its market value.

Concord Biotech Bonus Issue: What Happened to the Share Price?

Concord Biotech shares closed at ₹1,229.90 on November 3, according to the supplied market figures.

For a 1:1 bonus issue, the theoretical adjusted reference price is calculated by dividing the pre-bonus share price by two.

Bonus-adjusted reference price = ₹1,229.90 ÷ 2 = ₹614.95

The stock opened near ₹610 on Wednesday, representing a decline of approximately 0.8% compared with the theoretical adjusted reference price.

During the early session, the share price reportedly moved down to ₹595 before recovering to ₹623.65.

At ₹623.65, the price was approximately 1.4% above the theoretical adjusted reference price of ₹614.95.

The recovery from ₹595 to ₹623.65 was approximately 4.8%.

These calculations show why comparing Wednesday’s traded price directly with Tuesday’s unadjusted close can produce a misleading impression of the stock’s performance.

Concord Biotech Share Price: Before and After Bonus Adjustment

Source: Market figures supplied for November 4, 2026. Figures are subject to exchange verification and may not represent final closing prices.

The ex-bonus adjustment should also be distinguished from a stock split. Concord Biotech’s reported corporate action is a bonus issue, not a subdivision of the existing shares.

Both actions can result in a proportionate reduction in the quoted per-share price, but their legal and accounting mechanisms are different.

How Will the 1:1 Bonus Issue Affect Shareholders?

A bonus issue increases the number of shares held by eligible investors without requiring them to pay an additional subscription amount.

Consider an investor who owned 100 shares before the corporate action.

At the previous closing price of ₹1,229.90, the holding would have had a market value of ₹1,22,990.

Following the theoretical 1:1 adjustment, the investor would be entitled to hold 200 shares, each valued at approximately ₹614.95.

The total theoretical holding value would remain ₹1,22,990.

Example: Impact of Concord Biotech’s Bonus Shares

The example assumes the market price changes only because of the bonus adjustment.

In actual trading, the price can rise or fall because of investor demand, market sentiment, company developments and other factors.

The total investment value is therefore not guaranteed to remain exactly unchanged after trading resumes.

Concord Biotech Bonus Record Date: Who Is Eligible?

The reported record date for Concord Biotech’s 1:1 bonus issue is November 4, 2026.

A record date is the date on which a company determines the shareholders entitled to receive a particular corporate-action benefit.

Eligibility depends on the applicable ex-date, settlement rules and shareholder records maintained by the depositories and relevant intermediaries.

Investors who purchase shares on or after the ex-bonus date generally do not receive the bonus entitlement attached to the pre-adjustment shares.

Shareholders should check official exchange notices and communications from their depository participants to confirm their eligibility.

The actual credit of bonus shares into demat accounts follows the corporate-action process and applicable timelines.

Temporary discrepancies in displayed quantities, average purchase prices or portfolio returns may occur while broker systems update their records.

Why Can Trading Apps Show an Incorrect-Looking Loss?

Corporate actions can create confusion because brokerage platforms may update different parts of an investor’s portfolio at different times.

For instance, a platform might display the new ex-bonus market price before updating the investor’s total share quantity or historical reference price.

If the software continues comparing the new market price with the previous unadjusted close, the displayed percentage change could suggest an unusually large loss.

Similarly, portfolio profit-and-loss calculations may temporarily appear distorted if the bonus entitlement has not been fully reflected.

However, investors should not assume every displayed decline is merely a technical error.

The stock can still experience genuine price changes after the adjustment, and those changes should be measured against the appropriate adjusted reference price.

Investors can cross-check prices and corporate-action details through official exchange information and their brokerage’s corporate-action records.

Rakesh Jhunjhunwala Family’s Stake in Concord Biotech

Concord Biotech has attracted additional market attention because of its association with the family of late stock-market investor Rakesh Jhunjhunwala.

According to the supplied shareholding information, three discretionary trusts named after Jhunjhunwala’s children collectively held approximately 2.52 crore shares, representing a 24.10% stake before the reported bonus adjustment.

Following a 1:1 bonus issue, that holding would theoretically increase to approximately 5.04 crore shares, while the percentage ownership would remain unchanged, assuming no other shareholding changes.

At the reported market price of ₹623.65, the post-adjustment holding would have an indicative market value of roughly ₹3,143 crore.

This represents the calculated market value of the reported shares and does not indicate that the family received a corresponding cash payment.

The bonus allotment changes the number of shares held, not the proportionate ownership of shareholders who receive the bonus on equal terms.

The company’s association with a prominent investor family may draw market interest, but that connection alone should not be treated as a measure of investment quality.

Concord Biotech Q2 FY27 Results: Profit and Revenue Growth

Beyond the corporate action, Concord Biotech’s reported financial performance provides an additional consideration for investors assessing the company.

For the quarter ended September 2026, the pharmaceutical company reported a net profit of approximately ₹70.65 crore, representing year-on-year growth of 11.2%, according to the supplied results.

Revenue from operations reportedly increased 25.1% to ₹309.07 crore.

Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 17.9% to ₹104.81 crore.

However, EBITDA margin narrowed by approximately 207 basis points to 33.91%.

Concord Biotech Q2 FY27 Financial Highlights

Source: Quarterly figures provided in the underlying report; confirmation against the company’s official financial results is required.

The results indicate that revenue expanded faster than operating profit during the reported quarter.

Although EBITDA increased in absolute terms, the contraction in margin suggests that operating costs or changes in the revenue mix may have affected profitability.

The precise reasons for the margin movement should be established from the company’s management commentary and official results rather than inferred from the headline figures alone.

For long-term shareholders, profitability, operating cash flow, business expansion and the sustainability of margins are more important indicators of financial performance than the mechanical adjustment associated with a bonus issue.

Concord Biotech Share Price Performance and IPO History

Concord Biotech was incorporated in 1984 and operates in the biopharmaceutical sector, with activities involving research, development and manufacturing of pharmaceutical products, including active pharmaceutical ingredients (APIs).

The company entered the stock market in August 2023 through an IPO priced at ₹741 per share, according to the supplied historical information.

Its reported IPO size was approximately ₹1,550.52 crore.

Following a 1:1 bonus issue, the theoretical bonus-adjusted equivalent of the ₹741 IPO price becomes ₹370.50 per share.

At the reported market price of ₹623.65, this represents an increase of approximately 68.3% over that adjusted IPO price, excluding transaction charges and other investor-specific factors.

This comparison is based on the bonus adjustment described in the report and assumes no other relevant historical price adjustments.

The stock’s reported bonus-adjusted 52-week high was ₹807.03, recorded in August 2026, while its reported adjusted 52-week low was ₹493.53 in April 2026.

At ₹623.65, the share price was approximately 22.7% below the reported high and 26.4% above the reported low.

These historical figures should be cross-checked against adjusted exchange price series before use in investment analysis.

Are Concord Biotech Bonus Shares Taxable?

Under the general Indian income-tax treatment of bonus equity shares, receiving shares through a qualifying bonus allotment does not ordinarily trigger an immediate capital gains tax liability for the shareholder.

However, tax considerations can arise when the bonus shares are eventually sold.

For bonus shares covered by the relevant cost-of-acquisition provisions, the acquisition cost is generally treated as nil.

The holding period of bonus shares is ordinarily determined separately from the original shares and begins with the applicable allotment date.

Consequently, the eventual capital gain and its tax classification can differ between the original shares and the bonus shares.

The applicable treatment depends on the prevailing law, the type of shareholder and the specific transaction.

Investors should consult the relevant Income-tax Act provisions or a qualified tax professional before calculating liabilities arising from a sale.

Is Concord Biotech a Buy After the Bonus Issue?

A bonus issue alone does not make a stock fundamentally cheaper.

Although the market price per share declines proportionately, the number of shares increases, leaving the theoretical aggregate value of the holding unchanged at the moment of adjustment.

Therefore, a stock that traded at ₹1,229.90 before a 1:1 bonus adjustment is not automatically undervalued because its adjusted price is around ₹615.

Investors evaluating Concord Biotech should consider the company’s earnings outlook, API business performance, profitability, valuations, regulatory environment and competitive position.

They should also examine cash-flow generation and the sustainability of earnings growth.

Short-term trading movements around corporate-action dates can be influenced by changing liquidity, order flows and sentiment.

A bonus issue may improve accessibility by reducing the nominal trading price per share, but it does not independently create additional underlying business value.

Conclusion

Concord Biotech’s apparent 50% share-price decline on November 4, 2026, is largely explained by its reported 1:1 bonus share adjustment rather than a sudden collapse in the company’s value.

Eligible shareholders are entitled to one additional share for each share already held, while the theoretical market price adjusts proportionately.

With a pre-bonus closing price of ₹1,229.90, the corresponding theoretical adjusted reference price works out to ₹614.95.

The reported recovery to ₹623.65 during Wednesday’s session demonstrates why investors should compare ex-bonus trading prices with adjusted historical prices rather than unadjusted quotations.

For shareholders, the immediate priorities are to confirm eligibility, monitor the bonus share credit process and assess the company’s underlying business fundamentals.